REIN-2 clinical trial
Jump to navigation
Jump to search
Introduction
Design:
- multicentre, randomised controlled trial
- 338 patients with non-diabetic proteinuric nephropathies treated with ACE inhibitor ramipril (2.5-5 mg/day) median follow-up of 19 months
- conventional (diastolic <90 mm Hg; n=169) vs intensified (systolic/diastolic <130/80 mm Hg; n=169) blood-pressure control
dihydropyridine calcium-channel blocker felodipine (5-10 mg/day) used for intensified blood pressure control
Primary outcome:
- time to end-stage renal disease
Analysis by intention to treat
Results:
- 38/167 (23%) intensified group & 34/168 (20%) of conventional control progressed to end-stage renal disease (hazard ratio 1.00
- no added benefit of further blood-pressure reduction by felodipine
More general terms
Additional terms
References
- ↑ Journal Watch 25(9):72, 2005 Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005 Mar 12;365(9463):939-46. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15766995
De Jong PE, de Zeeuw D. Renoprotective therapy: is it blood pressure or albuminuria that matters? Lancet. 2005 Mar 12;365(9463):913-4. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15766975